Study of UX701 Gene Transfer for the Treatment of Wilson Disease

Last updated: November 25, 2024
Sponsor: Ultragenyx Pharmaceutical Inc
Overall Status: Active - Not Recruiting

Phase

1/2

Condition

Liver Disease

Wilson's Disease

Kidney Failure

Treatment

UX701

Placebo

Clinical Study ID

NCT04884815
UX701-CL301
2020-005266-34
2022-502873-40-00
  • Ages > 18
  • All Genders

Study Summary

The primary objectives of this study are to evaluate the safety of single IV doses of UX701 in patients with Wilson disease, to select the UX701 dose with the best benefit/risk profile based on the totality of safety and efficacy data and to evaluate the effect of UX701 on copper regulation.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  • Confirmed diagnosis of Wilson disease

  • Stable Wilson disease as evidenced by ongoing copper chelator (ie, penicillamine,trientine) and/or zinc therapy for at least 6 months at screening, with nomedication or dose changes for at least 6 months at screening.

  • Ongoing restriction of high copper containing foods for at least 6 months atScreening, continued through study participation.

  • Willing and able to comply with all study procedures and requirements, includingfrequent blood collection, total urine collection over a 24-hour period,patient-reported outcome assessments, and long-term follow-up

Exclusion

Key Exclusion Criteria:

  • Detectable pre-existing antibodies to the AAV9 capsid.

  • Stage 1 only: History of copper chelator or zinc therapy noncompliance, in theInvestigator's judgment, within 6 months prior to Screening.

  • History of liver transplant.

  • Decompensated hepatic cirrhosis or presence of advanced liver disease as evidencedby portal hypertension, ascites, splenomegaly, esophageal varices, hepaticencephalopathy.

  • Significant hepatic inflammation as evidenced by laboratory abnormalities.

  • Model for End-Stage Liver Disease (MELD) score > 13.

  • Hemoglobin < 9 g/dL

  • Presence of Stage 3 or higher chronic kidney disease based on estimated glomerularfiltration rate < 60 mL/min/1.73 m2.

  • Marked neurological deficit or compromise that, in the Investigator's opinion, wouldinterfere with the subject's safety or ability to participate in the study.

  • Moderate to severe depression, recent or active suicidal ideation with intent orsuicidal behavior, psychosis, or unstable psychiatric illness.

  • Participation in another gene transfer study or use of another gene transfer productbefore or during study participation.

  • Subjects with known hypersensitivity to amide-containing local anesthetics areexcluded from participating in the optional liver biopsy substudy.

Note: Other protocol defined Inclusion/ Exclusion criteria may apply

Study Design

Total Participants: 78
Treatment Group(s): 2
Primary Treatment: UX701
Phase: 1/2
Study Start date:
September 27, 2021
Estimated Completion Date:
November 30, 2031

Study Description

This study is a randomized, double-blind, placebo-controlled, seamless, adaptive Phase 1/2/3 clinical study of UX701 in patients with Wilson disease.

Stage 1 (Phase 1/2) is a nonrandomized, open-label safety and dose-finding stage designed to evaluate the safety and efficacy of 3 dose levels of UX701 to establish initial safety of UX701 and select a safe and efficacious dose for further evaluation. Stage 2 (Phase 3) is a randomized, double-blind, placebo-controlled stage designed to evaluate the safety and efficacy of UX701 using the dose selected in Stage 1. Stage 3 is designed to evaluate the long-term safety, efficacy, and clinical benefit of UX701. All participants will be followed for at least 5 years from the time of UX701 administration.

Participants who receive UX701 will receive premedications and prophylactic oral corticosteroids. Participants who receive placebo will receive premedications and placebo oral corticosteroids to maintain the study blind.

Connect with a study center

  • Gordon and Leslie Diamond Health Care Centre

    Vancouver, British Columbia V5Z 1M9
    Canada

    Site Not Available

  • Centro Hospitalar Universitário Lisboa Norte

    Lisboa, Lisbon 1649-035
    Portugal

    Site Not Available

  • Centro Hospitalar Universitário de São João

    Porto, 4200-319
    Portugal

    Site Not Available

  • Hospital Universitario Vall d'Hebron - PPDS

    Barcelona, 08035
    Spain

    Site Not Available

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, 46026
    Spain

    Site Not Available

  • Kings College NHS Foundation

    London, Surrey SE5 9RS
    United Kingdom

    Site Not Available

  • University of California Los Angeles

    Los Angeles, California 90095
    United States

    Site Not Available

  • Stanford University

    Redwood City, California 94063
    United States

    Site Not Available

  • University of California Davis

    Sacramento, California 95817-1348
    United States

    Site Not Available

  • University of Miami

    Miami, Florida 33124
    United States

    Site Not Available

  • Northwestern University

    Chicago, Illinois 60611
    United States

    Site Not Available

  • Indiana University

    Indianapolis, Indiana 46202
    United States

    Site Not Available

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

  • University of Michigan

    Ann Arbor, Michigan 48109
    United States

    Site Not Available

  • Duke University Medical Center

    Durham, North Carolina 27710
    United States

    Site Not Available

  • Vanderbilt University Medical Center

    Nashville, Tennessee 37212-2700
    United States

    Site Not Available

  • University of Utah

    Salt Lake City, Utah 84132
    United States

    Site Not Available

  • University of Virginia

    Charlottesville, Virginia 22908-0001
    United States

    Site Not Available

  • Seattle Children's Hospital

    Seattle, Washington 98105
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.